ESR1 and breast cancer: Under NCCN guidelines, adjuvant endocrine therapy is recommended for hormone receptor positive BC, including selective estrogen receptor modulator (SERM), selective estrogen receptor downregulator (SERD), aromatase inhibitor (AI), and GnHa.